ClinicalTrials.Veeva

Find clinical trials for Adenocarcinoma in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Stomach Cancer
Colorectal Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near Nashville, TN, USA:

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for ...

Active, not recruiting
Pancreas Adenocarcinoma
Drug: Gemcitabine
Drug: nab paclitaxel

Phase 3

NovoCure
NovoCure

Nashville, Tennessee, United States and 197 other locations

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC)....

Active, not recruiting
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Drug: Leucovorin
Drug: ZW25 (Zanidatamab)

Phase 2

Jazz Pharmaceuticals
Jazz Pharmaceuticals

Nashville, Tennessee, United States and 20 other locations

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7...

Active, not recruiting
Pancreatic Ductal Adenocarcinoma
NRAS G12D
Drug: ELI-002 2P

Phase 1

Elicio Therapeutics
Elicio Therapeutics

Nashville, Tennessee, United States and 9 other locations

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Drug: Evorpacept (ALX148)
Drug: Trastuzumab

Phase 2, Phase 3

ALX Oncology

Nashville, Tennessee, United States and 54 other locations

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Drug: Capecitabine
Drug: Fluorouracil

Phase 3

Arcus Biosciences
Arcus Biosciences

Nashville, Tennessee, United States and 212 other locations

Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02)

This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-...

Active, not recruiting
Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: paclitaxel
Drug: trastuzumab

Phase 2, Phase 3

Seagen
Seagen

Nashville, Tennessee, United States and 47 other locations

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...

Enrolling
Colorectal Adenocarcinoma
Pancreatic Adenocarcinoma
Drug: 5-fluorouracil
Drug: Irinotecan

Phase 1

Inhibrx

Nashville, Tennessee, United States and 18 other locations

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C*08:02-restricted T cell receptor (TCR), targ...

Enrolling
Pancreatic Ductal Adenocarcinoma
Endometrial Cancer
Biological: NT-112: Autologous, engineered T Cells targeting KRAS G12D

Phase 1

Neogene Therapeutics

Nashville, Tennessee, United States and 2 other locations

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC (ESOGUARDBE2)

Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plu...

Enrolling
Esophageal Adenocarcinoma
Barretts Esophagus With Dysplasia
Diagnostic Test: Esophagogastroduodenoscopy
Device: EsoGuard (lab assay)
Lucid Diagnostics

Nashville, Tennessee, United States and 37 other locations

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)

in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuva...

Enrolling
Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer Metastatic
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 2, Phase 3

Panbela Therapeutics

Nashville, Tennessee, United States and 91 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems